{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:42:21Z","timestamp":1792255341105,"version":"4.4.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00676-0","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:06:04Z","timestamp":1792224364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Nanosizing: Mechanism-Guided Design and Rational Selection of Polymeric and Lipid Nanocarriers for Translatable Drug Delivery"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8195-0327","authenticated-orcid":false,"given":"Bishal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhisekh","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6564-9650","authenticated-orcid":false,"given":"Rajesh","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigyasa","family":"Jayaswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"9","key":"676_CR1","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/tx200211v","volume":"24","author":"NA Meanwell","year":"2011","unstructured":"Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol. 2011;24(9):1420\u201356. https:\/\/doi.org\/10.1021\/tx200211v.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"676_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.112.005660","volume":"65","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315\u2013499. https:\/\/doi.org\/10.1124\/pr.112.005660.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"676_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413\u201320. https:\/\/doi.org\/10.1023\/A:1016212804288.","journal-title":"Pharm Res"},{"issue":"1","key":"676_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijpharm.2012.11.026","volume":"453","author":"J Bevernage","year":"2013","unstructured":"Bevernage J, Brouwers J, Brewster ME, Augustijns P. Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int J Pharm. 2013;453(1):25\u201335. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.11.026.","journal-title":"Int J Pharm"},{"issue":"8","key":"676_CR5","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/jps.21650","volume":"98","author":"J Brouwers","year":"2009","unstructured":"Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549\u201372. https:\/\/doi.org\/10.1002\/jps.21650.","journal-title":"J Pharm Sci"},{"issue":"3","key":"676_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrd2197","volume":"6","author":"CJH Porter","year":"2007","unstructured":"Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231\u201348. https:\/\/doi.org\/10.1038\/nrd2197.","journal-title":"Nat Rev Drug Discov"},{"key":"676_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","volume":"57","author":"ES Kostewicz","year":"2014","unstructured":"Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:342\u201366. https:\/\/doi.org\/10.1016\/j.ejps.2013.08.024.","journal-title":"Eur J Pharm Sci"},{"key":"676_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejpb.2018.12.010","volume":"136","author":"J Butler","year":"2019","unstructured":"Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, et al. In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. 2019;136:70\u201383. https:\/\/doi.org\/10.1016\/j.ejpb.2018.12.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"676_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"key":"676_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nmat2442","volume":"8","author":"AE Nel","year":"2009","unstructured":"Nel AE, M\u00e4dler L, Velegol D, Xia T, Hoek EMV, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8:543\u201357. https:\/\/doi.org\/10.1038\/nmat2442.","journal-title":"Nat Mater"},{"key":"676_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","volume":"14","author":"A Albanese","year":"2012","unstructured":"Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1\u201316. https:\/\/doi.org\/10.1146\/annurev-bioeng-071811-150124.","journal-title":"Annu Rev Biomed Eng"},{"issue":"10","key":"676_CR12","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1021\/acs.molpharmaceut.3c00526","volume":"20","author":"DE Moseson","year":"2023","unstructured":"Moseson DE, Taylor LS. Crystallinity: a complex critical quality attribute of amorphous solid dispersions. Mol Pharm. 2023;20(10):4802\u201325. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00526.","journal-title":"Mol Pharm"},{"issue":"4","key":"676_CR13","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","volume":"116","author":"N Kamaly","year":"2016","unstructured":"Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602\u201363. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00346.","journal-title":"Chem Rev"},{"issue":"33","key":"676_CR14","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.0801763105","volume":"105","author":"SEA Gratton","year":"2008","unstructured":"Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613\u20138. https:\/\/doi.org\/10.1073\/pnas.0801763105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"676_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/polym13071027","volume":"13","author":"V De Leo","year":"2021","unstructured":"De Leo V, Milano F, Agostiano A, Catucci L. Recent advancements in polymer\/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polym (Basel). 2021;13(7):1027. https:\/\/doi.org\/10.3390\/polym13071027.","journal-title":"Polym (Basel)"},{"issue":"3","key":"676_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2022","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, Carreira B, Pozzi S, Ac\u00farcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500\u201325. https:\/\/doi.org\/10.1007\/s13346-021-01024-2.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"676_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.043.","journal-title":"J Control Release"},{"issue":"6","key":"676_CR18","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s11095-009-9860-z","volume":"26","author":"NL Trevaskis","year":"2009","unstructured":"Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, et al. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res. 2009;26(6):1486\u201395. https:\/\/doi.org\/10.1007\/s11095-009-9860-z.","journal-title":"Pharm Res"},{"issue":"8","key":"676_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V","volume":"89","author":"SM Caliph","year":"2000","unstructured":"Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci. 2000;89(8):1073\u201384. https:\/\/doi.org\/10.1002\/1520-6017(200008)89:8%3C1073::AID-JPS12%3E3.0.CO;2-V.","journal-title":"J Pharm Sci"},{"issue":"3","key":"676_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","volume":"10","author":"MS Taha","year":"2020","unstructured":"Taha MS, Padmakumar S, Singh A, Amiji MM. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation. Drug Deliv Transl Res. 2020;10(3):766\u201390. https:\/\/doi.org\/10.1007\/s13346-020-00744-1.","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"676_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"676_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"12","key":"676_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nnano.2012.207","volume":"7","author":"MP Monopoli","year":"2012","unstructured":"Monopoli MP, \u00c5berg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7(12):779\u201386. https:\/\/doi.org\/10.1038\/nnano.2012.207.","journal-title":"Nat Nanotechnol"},{"issue":"Pt A","key":"676_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.09.012.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"676_CR25","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/jbm.b.33648","volume":"105","author":"Y Xu","year":"2017","unstructured":"Xu Y, Kim CS, Saylor DM, Koo D. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: a review of experiments and theories. J Biomed Mater Res B Appl Biomater. 2017;105(6):1692\u2013716. https:\/\/doi.org\/10.1002\/jbm.b.33648.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"676_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.fct.2018.01.017","volume":"113","author":"S Kaddah","year":"2018","unstructured":"Kaddah S, Khreich N, Kaddah F, Charcosset C, Greige-Gerges H. Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem Toxicol. 2018;113:40\u20138. https:\/\/doi.org\/10.1016\/j.fct.2018.01.017.","journal-title":"Food Chem Toxicol"},{"issue":"Suppl 1","key":"676_CR27","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","volume":"54","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131\u201355. https:\/\/doi.org\/10.1016\/S0169-409X(02)00118-7.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"676_CR28","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","volume":"18","author":"K Paunovska","year":"2018","unstructured":"Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, et al. A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation. Nano Lett. 2018;18(3):2148\u201357. https:\/\/doi.org\/10.1021\/acs.nanolett.8b00432.","journal-title":"Nano Lett"},{"issue":"2","key":"676_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"14","author":"N Desai","year":"2012","unstructured":"Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282\u201395. https:\/\/doi.org\/10.1208\/s12248-012-9339-4.","journal-title":"AAPS J"},{"key":"676_CR30","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau NM, Huft J, Lin PJC, Chen S, Leung AKK, Leaver TJ, et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids. 2012;1:e37. https:\/\/doi.org\/10.1038\/mtna.2012.28.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"676_CR31","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1021\/ja301621z","volume":"134","author":"D Chen","year":"2012","unstructured":"Chen D, Love KT, Chen Y, Eltoukhy AA, Kastrup C, Sahay G, et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012;134(16):6948\u201351. https:\/\/doi.org\/10.1021\/ja301621z.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"676_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.addr.2007.04.012","volume":"59","author":"RH Muller","year":"2007","unstructured":"Muller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59(6):522\u201330. https:\/\/doi.org\/10.1016\/j.addr.2007.04.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"676_CR33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s44222-025-00321-6","volume":"3","author":"Y Chen","year":"2025","unstructured":"Chen Y, Su YC, Roffler SR. Polyethylene glycol immunogenicity in nanomedicine. Nat Rev Bioeng. 2025;3:742\u201360. https:\/\/doi.org\/10.1038\/s44222-025-00321-6.","journal-title":"Nat Rev Bioeng"},{"issue":"3","key":"676_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s13346-022-01262-y","volume":"13","author":"DA Dri","year":"2023","unstructured":"Dri DA, Rinaldi F, Carafa M, Marianecci C. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes. Drug Deliv Transl Res. 2023;13(3):757\u201369. https:\/\/doi.org\/10.1007\/s13346-022-01262-y.","journal-title":"Drug Deliv Transl Res"},{"key":"676_CR35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3389\/fphar.2018.00790","volume":"9","author":"S Hua","year":"2018","unstructured":"Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790. https:\/\/doi.org\/10.3389\/fphar.2018.00790.","journal-title":"Front Pharmacol"},{"issue":"2","key":"676_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u2013the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117.","journal-title":"J Control Release"},{"issue":"12","key":"676_CR37","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084\u20137. https:\/\/doi.org\/10.1038\/s41565-019-0591-y.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"676_CR38","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143. https:\/\/doi.org\/10.1002\/btm2.10143.","journal-title":"Bioeng Transl Med"},{"issue":"10","key":"676_CR39","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119\u201326. https:\/\/doi.org\/10.11124\/JBIES-20-00167.","journal-title":"JBI Evid Synth"},{"key":"676_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10:39. https:\/\/doi.org\/10.1186\/s13643-020-01542-z.","journal-title":"Syst Rev"},{"issue":"1","key":"676_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348. https:\/\/doi.org\/10.1016\/j.addr.2012.09.037.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"676_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. https:\/\/doi.org\/10.3390\/pharmaceutics9020012.","journal-title":"Pharmaceutics"},{"issue":"5","key":"676_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419\u201336. https:\/\/doi.org\/10.2165\/00003088-200342050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"676_CR44","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","volume":"46","author":"I Bekersky","year":"2002","unstructured":"Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828\u201333. https:\/\/doi.org\/10.1128\/AAC.46.3.828-833.2002.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"676_CR45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","volume":"46","author":"I Bekersky","year":"2002","unstructured":"Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after intravenous liposomal amphotericin B and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002;46(3):834\u201340. https:\/\/doi.org\/10.1128\/AAC.46.3.834-840.2002.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"676_CR46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"TJ Walsh","year":"1999","unstructured":"Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340(10):764\u201371. https:\/\/doi.org\/10.1056\/NEJM199903113401004.","journal-title":"N Engl J Med"},{"issue":"5","key":"676_CR47","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1073\/pnas.0608611104","volume":"104","author":"SK Lai","year":"2007","unstructured":"Lai SK, O\u2019Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482\u20137. https:\/\/doi.org\/10.1073\/pnas.0608611104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"138","key":"676_CR48","doi-asserted-by":"publisher","first-page":"138ra79","DOI":"10.1126\/scitranslmed.3003453","volume":"4","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra79. https:\/\/doi.org\/10.1126\/scitranslmed.3003453.","journal-title":"Sci Transl Med"},{"issue":"10","key":"676_CR49","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nnano.2013.181","volume":"8","author":"S Tenzer","year":"2013","unstructured":"Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772\u201381. https:\/\/doi.org\/10.1038\/nnano.2013.181.","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"676_CR50","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1021\/ja2084338","volume":"134","author":"CD Walkey","year":"2012","unstructured":"Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc. 2012;134(4):2139\u201347. https:\/\/doi.org\/10.1021\/ja2084338.","journal-title":"J Am Chem Soc"},{"issue":"3","key":"676_CR51","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1021\/nn406018q","volume":"8","author":"CD Walkey","year":"2014","unstructured":"Walkey CD, Olsen JB, Song F, Liu R, Guo H, Olsen DWH, et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano. 2014;8(3):2439\u201355. https:\/\/doi.org\/10.1021\/nn406018q.","journal-title":"ACS Nano"},{"issue":"2","key":"676_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nnano.2012.237","volume":"8","author":"A Salvati","year":"2013","unstructured":"Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137\u201343. https:\/\/doi.org\/10.1038\/nnano.2012.237.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"676_CR53","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nbt.2612","volume":"31","author":"J Gilleron","year":"2013","unstructured":"Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638\u201346. https:\/\/doi.org\/10.1038\/nbt.2612.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"676_CR54","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nbt.3298","volume":"33","author":"A Wittrup","year":"2015","unstructured":"Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, et al. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol. 2015;33(8):870\u20136. https:\/\/doi.org\/10.1038\/nbt.3298.","journal-title":"Nat Biotechnol"},{"issue":"16","key":"676_CR55","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","volume":"118","author":"MP Stewart","year":"2018","unstructured":"Stewart MP, Langer R, Jensen KF. Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts. Chem Rev. 2018;118(16):7409\u2013531. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00678.","journal-title":"Chem Rev"},{"issue":"3","key":"676_CR56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polym (Basel). 2011;3(3):1377\u201397. https:\/\/doi.org\/10.3390\/polym3031377.","journal-title":"Polym (Basel)"},{"issue":"3","key":"676_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejpb.2012.04.007","volume":"81","author":"A Bernkop-Schnurch","year":"2012","unstructured":"Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81(3):463\u20139. https:\/\/doi.org\/10.1016\/j.ejpb.2012.04.007.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"676_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","volume":"24","author":"VP Torchilin","year":"2007","unstructured":"Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1\u201316. https:\/\/doi.org\/10.1007\/s11095-006-9132-0.","journal-title":"Pharm Res"},{"issue":"1\u20133","key":"676_CR59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0168-3659(93)90172-2","volume":"24","author":"K Kataoka","year":"1993","unstructured":"Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1993;24(1\u20133):119\u201332. https:\/\/doi.org\/10.1016\/0168-3659(93)90172-2.","journal-title":"J Control Release"},{"issue":"12","key":"676_CR60","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","volume":"6","author":"H Cabral","year":"2011","unstructured":"Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815\u201323. https:\/\/doi.org\/10.1038\/nnano.2011.166.","journal-title":"Nat Nanotechnol"},{"issue":"15","key":"676_CR61","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.addr.2005.09.018","volume":"57","author":"S Svenson","year":"2005","unstructured":"Svenson S, Tomalia DA. Dendrimers in biomedical applications\u2013reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106\u201329. https:\/\/doi.org\/10.1016\/j.addr.2005.09.018.","journal-title":"Adv Drug Deliv Rev"},{"key":"676_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13036-022-00298-5","volume":"16","author":"J Wang","year":"2022","unstructured":"Wang J, Li B, Qiu L, Qiao X, Yang H. Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng. 2022;16:18. https:\/\/doi.org\/10.1186\/s13036-022-00298-5.","journal-title":"J Biol Eng"},{"issue":"3","key":"676_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/0975-7406.130965","volume":"6","author":"K Madaan","year":"2014","unstructured":"Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6(3):139\u201350. https:\/\/doi.org\/10.4103\/0975-7406.130965.","journal-title":"J Pharm Bioallied Sci"},{"issue":"1","key":"676_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","volume":"172","author":"AS Abu Lila","year":"2013","unstructured":"Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172(1):38\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2013.07.026.","journal-title":"J Control Release"},{"issue":"10","key":"676_CR65","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1096\/fj.02-0088com","volume":"16","author":"J Panyam","year":"2002","unstructured":"Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10):1217\u201326. https:\/\/doi.org\/10.1096\/fj.02-0088com.","journal-title":"FASEB J"},{"issue":"9","key":"676_CR66","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s13346-022-01157-y","volume":"12","author":"AKO \u00c5slund","year":"2022","unstructured":"\u00c5slund AKO, Vandebriel RJ, Caputo F, De Jong WH, Delmaar C, Hyldbakk A, et al. A comparative biodistribution study of polymeric and lipid-based nanoparticles. Drug Deliv Transl Res. 2022;12(9):2114\u201331. https:\/\/doi.org\/10.1007\/s13346-022-01157-y.","journal-title":"Drug Deliv Transl Res"},{"key":"676_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"JI Hare","year":"2017","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25\u201338. https:\/\/doi.org\/10.1016\/j.addr.2016.04.025.","journal-title":"Adv Drug Deliv Rev"},{"key":"676_CR68","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. https:\/\/doi.org\/10.3389\/fphar.2015.00286.","journal-title":"Front Pharmacol"},{"issue":"19","key":"676_CR69","doi-asserted-by":"publisher","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","volume":"115","author":"BS Pattni","year":"2015","unstructured":"Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938\u201366. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00046.","journal-title":"Chem Rev"},{"issue":"7","key":"676_CR70","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.013.","journal-title":"Mol Ther"},{"issue":"1","key":"676_CR71","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH Muller","year":"2000","unstructured":"Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161\u201377. https:\/\/doi.org\/10.1016\/S0939-6411(00)00087-4.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"676_CR72","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","volume":"366","author":"J Pardeike","year":"2009","unstructured":"Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1\u20132):170\u201384. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.10.003.","journal-title":"Int J Pharm"},{"issue":"2","key":"676_CR73","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172\u20136. https:\/\/doi.org\/10.1038\/nbt.1602.","journal-title":"Nat Biotechnol"},{"issue":"34","key":"676_CR74","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529\u201333. https:\/\/doi.org\/10.1002\/anie.201203263.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"676_CR75","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","volume":"12","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano. 2018;12(5):4787\u201395. https:\/\/doi.org\/10.1021\/acsnano.8b01516.","journal-title":"ACS Nano"},{"issue":"1","key":"676_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2\u201312. https:\/\/doi.org\/10.1021\/acs.accounts.1c00544.","journal-title":"Acc Chem Res"},{"issue":"6","key":"676_CR77","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26(6):1509\u201319. https:\/\/doi.org\/10.1016\/j.ymthe.2018.03.010.","journal-title":"Mol Ther"},{"issue":"4","key":"676_CR78","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"key":"676_CR79","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586.","journal-title":"Int J Pharm"},{"key":"676_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1\u201311. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.013.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"676_CR81","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"676_CR82","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"issue":"1","key":"676_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"issue":"27","key":"676_CR84","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"issue":"5","key":"676_CR85","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"issue":"3","key":"676_CR86","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdh097.","journal-title":"Ann Oncol"},{"issue":"7","key":"676_CR87","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","volume":"16","author":"DW Northfelt","year":"1998","unstructured":"Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445\u201351. https:\/\/doi.org\/10.1200\/JCO.1998.16.7.2445.","journal-title":"J Clin Oncol"},{"key":"676_CR88","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Chen K, Jiang T, Wu Y, Wu Z, Ying H, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nat Commun. 2024;15:10804. https:\/\/doi.org\/10.1038\/s41467-024-55072-6.","journal-title":"Nat Commun"},{"key":"676_CR89","doi-asserted-by":"publisher","first-page":"113806","DOI":"10.1016\/j.addr.2021.05.016","volume":"175","author":"P Bannigan","year":"2021","unstructured":"Bannigan P, Aldeghi M, Bao Z, Hase F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. https:\/\/doi.org\/10.1016\/j.addr.2021.05.016.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"676_CR90","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337. https:\/\/doi.org\/10.1038\/nrc.2016.108.","journal-title":"Nat Rev Cancer"},{"key":"676_CR91","doi-asserted-by":"publisher","first-page":"2630014","DOI":"10.1142\/S1793984426300141","volume":"16","author":"B Singh","year":"2026","unstructured":"Singh B, Sah A, Ghosh B, Kumar D. Lymphatic-targeted nanoparticle drug delivery for early cancer metastasis and lymphoma: bypassing hepatic first-pass metabolism. Nano LIFE. 2026;16:2630014. https:\/\/doi.org\/10.1142\/S1793984426300141.","journal-title":"Nano LIFE"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00676-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00676-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00676-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:02:23Z","timestamp":1792252943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00676-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["676"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00676-0","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"94"}}